JP2022525013A - Ｈｉｖ療法において有用な化合物 - Google Patents

Ｈｉｖ療法において有用な化合物 Download PDF

Info

Publication number
JP2022525013A
JP2022525013A JP2021552772A JP2021552772A JP2022525013A JP 2022525013 A JP2022525013 A JP 2022525013A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A JP2022525013 A JP 2022525013A
Authority
JP
Japan
Prior art keywords
mmol
acid
fluoro
alkyl
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021552772A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020178767A5 (https=
JP2022525013A5 (https=
Inventor
マルタ、アリシア、デ、ラ、ローザ
ジョン、エフ．ミラー
デイビッド、テメルコフ
エミール、ジョハン、ベルジュイセン
ビー．ナラシムフル、ナイドゥ
ビセンテ、サマノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022525013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd, ViiV Healthcare Co filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2022525013A publication Critical patent/JP2022525013A/ja
Publication of JPWO2020178767A5 publication Critical patent/JPWO2020178767A5/ja
Publication of JP2022525013A5 publication Critical patent/JP2022525013A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021552772A 2019-03-06 2020-03-04 Ｈｉｖ療法において有用な化合物 Ceased JP2022525013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (3)

Publication Number Publication Date
JP2022525013A true JP2022525013A (ja) 2022-05-11
JPWO2020178767A5 JPWO2020178767A5 (https=) 2024-07-16
JP2022525013A5 JP2022525013A5 (https=) 2024-07-16

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552772A Ceased JP2022525013A (ja) 2019-03-06 2020-03-04 Ｈｉｖ療法において有用な化合物

Country Status (22)

Country Link
US (4) US12240853B2 (https=)
EP (1) EP3934760A1 (https=)
JP (1) JP2022525013A (https=)
KR (1) KR20210136052A (https=)
CN (1) CN113811360A (https=)
AR (1) AR118240A1 (https=)
AU (1) AU2020231934B2 (https=)
BR (1) BR112021017604A2 (https=)
CA (1) CA3132112A1 (https=)
CL (1) CL2021002309A1 (https=)
CO (1) CO2021012579A2 (https=)
CR (1) CR20210460A (https=)
EA (1) EA202192433A1 (https=)
IL (1) IL285894A (https=)
MA (1) MA55200A (https=)
MX (1) MX2021010700A (https=)
PE (1) PE20212089A1 (https=)
PH (1) PH12021500034A1 (https=)
SG (1) SG11202109253SA (https=)
TW (1) TW202102233A (https=)
WO (1) WO2020178767A1 (https=)
ZA (1) ZA202106096B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541667A (ja) * 2019-07-27 2022-09-26 ブリー バイオサイエンシーズ， インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
JP2025541056A (ja) * 2023-01-30 2025-12-18 メルク・シャープ・アンド・ドーム・エルエルシー ４’－置換ヌクレオシド逆転写酵素阻害剤のプロドラッグ

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221037A1 (es) 2019-09-11 2022-06-17 Scripps Research Inst Profarmacos antivirales y composiciones farmaceuticas de los mismos
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
CN116710465A (zh) 2021-01-25 2023-09-05 腾盛博药生物科技有限公司 腺苷衍生物和包含其的药物组合物
TW202237146A (zh) * 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090349A1 (ja) * 2004-03-24 2005-09-29 Yamasa Corporation ４’−ｃ−置換−２−ハロアデノシン誘導体
JP2018532726A (ja) * 2015-09-23 2018-11-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE250623T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-purin-nukleoside
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US9770035B2 (en) 2011-10-06 2017-09-26 Dow Agrosciences Llc Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests
AU2013235220C1 (en) 2011-12-22 2019-03-28 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
EP3055319A4 (en) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
LT3160476T (lt) 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016066283A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
EP3529254B1 (en) 2016-11-03 2023-02-22 Laurence I. Wu Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019199667A2 (en) 2018-04-09 2019-10-17 Keaney Gregg F Certain pladienolide compounds and methods of use
WO2020031131A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
ES2971482T3 (es) 2019-03-06 2024-06-05 Greentech Global Pte Ltd Dispersiones líquidas para haluros de acilo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090349A1 (ja) * 2004-03-24 2005-09-29 Yamasa Corporation ４’−ｃ−置換−２−ハロアデノシン誘導体
JP2018532726A (ja) * 2015-09-23 2018-11-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 9, JPN6024013317, 1998, pages 311 - 323, ISSN: 0005437055 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541667A (ja) * 2019-07-27 2022-09-26 ブリー バイオサイエンシーズ， インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
JP2025541056A (ja) * 2023-01-30 2025-12-18 メルク・シャープ・アンド・ドーム・エルエルシー ４’－置換ヌクレオシド逆転写酵素阻害剤のプロドラッグ

Also Published As

Publication number Publication date
AU2020231934B2 (en) 2023-04-20
CO2021012579A2 (es) 2021-10-20
MX2021010700A (es) 2021-10-01
WO2020178767A1 (en) 2020-09-10
EP3934760A1 (en) 2022-01-12
CA3132112A1 (en) 2020-09-10
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
US20260035371A1 (en) 2026-02-05
IL285894A (en) 2021-10-31
ZA202106096B (en) 2023-03-29
MA55200A (fr) 2022-01-12
CR20210460A (es) 2022-02-03
CN113811360A (zh) 2021-12-17
EA202192433A1 (ru) 2021-12-28
KR20210136052A (ko) 2021-11-16
CL2021002309A1 (es) 2022-09-20
AR118240A1 (es) 2021-09-22
PE20212089A1 (es) 2021-11-04
US20230174534A1 (en) 2023-06-08
US12240853B2 (en) 2025-03-04
US20220411425A1 (en) 2022-12-29
TW202102233A (zh) 2021-01-16
US20240182473A1 (en) 2024-06-06
BR112021017604A2 (pt) 2021-11-16
SG11202109253SA (en) 2021-09-29
PH12021500034A1 (en) 2022-06-06

Similar Documents

Publication Publication Date Title
JP2022525013A (ja) Ｈｉｖ療法において有用な化合物
TWI583696B (zh) 樺腦（ｂｅｔｕｌｉｎ）衍生物
US8802727B2 (en) Pharmaceutically acceptable salts of betulinic acid derivatives
JP2021534112A (ja) Ｈｉｖ療法に有用な化合物
US20210323993A1 (en) Compounds Useful in HIV Therapy
WO2021038509A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
JP2021515771A (ja) Ｈｉｖ療法に有用な化合物
US20140221328A1 (en) Pharmaceutically acceptable salts of novel betulinic acid derivatives
KR20140101869A (ko) 베툴린의 프로페노에이트 유도체
US20230151049A1 (en) Compounds Useful in HIV Therapy
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
JP2022543319A (ja) Ｈｉｖ治療に有用な化合物
KR20180028535A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240405

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241011

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250221